Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination.
Chan
P
P
Department of Neurology, Sun Yat-Sen University of Medical Sciences, Guangzhou, People's Republic of China.
D015765:Almitrine / Q000627:therapeutic use*; D000818:Animals; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control; D004338:Drug Combinations; D002534:Hypoxia, Brain / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D046948:Secologanin Tryptamine Alkaloids; D016896:Treatment Outcome; D015016:Yohimbine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D004338:Drug Combinations; D018696:Neuroprotective Agents; D010879:Piperazines; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine; C005709:raubasine; C037558:almitrine, raubasine drug combination; D015765:Almitrine